Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia

References

• Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43:182–86. doi:10.1053/jinf.2001.0904.
   PubMed Web of Science ®Google Scholar
• Pelton SI, Weycker D, Farkouh RA, Strutton DR, Shea KM, Edelsberg J. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2014;59:615–23. doi:10.1093/cid/ciu348.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;2014(58):e44–e100.
   Google Scholar
• Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, et al. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine. 2015;33:6054–60. doi:10.1016/j.vaccine.2015.07.069.
   PubMed Web of Science ®Google Scholar
• Ishiwada N, Hishiki H, Nagasawa K, Naito S, Sato Y, Chang B, Sasaki Y, Kimura K, Ohnishi M, Shibayama K. The incidence of pediatric invasive Haemophilus influenzae and pneumococcal disease in Chiba prefecture, Japan before and after the introduction of conjugate vaccines. Vaccine. 2014;32:5425–3541. doi:10.1016/j.vaccine.2014.07.100.
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EAL, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012;205:1408–16. doi:10.1093/infdis/jis212.
   PubMed Web of Science ®Google Scholar
• Nived P, Jørgensen CS, Settergren B. Vaccination status and immune response to 13-valent pneumococcal conjugate vaccine in asplenic individuals. Vaccine. 2015;33:1688–94. doi:10.1016/j.vaccine.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Takeshita K, Ishiwada N. An e-mail questionnaire survey on current Haemophilus influenzae type b and pneumococcal vaccination status for Japanese high-risk children. J Pediatr Infect Dis Immunol. 2018;30:57–62. (Japanese).
   Google Scholar
• WHO (World Health Organization). Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). 2011;1–29. [accessed 2021 June 22]. https://www.vaccine.uab.edu/uploads/mdocs/ELISAProtocol(007sp).pdf.
   Google Scholar
• Henckaerts I, Goldblatt D, Ashton L, Poolman J, Biologicals G. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22f inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356–60. doi:10.1128/CVI.13.3.356-360.2006.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Ishiwada N, Hishiki H, Tanaka J, Akeda Y, Shimojo N, Oishi K, Kohno Y. IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations. J Infect Chemother. 2014;20:794–98. doi:10.1016/j.jiac.2014.08.027.
   PubMed Web of Science ®Google Scholar
• Nahm MH, Burton RL. Protocol for multiplexed opsonophagocytic killing assay (UAB-MOPA) for antibodies against Streptococcus pneumoniae. UAB-MOPA-E.02. 2009;1–43. [accessed 2011 June  22]. https://www.vaccine.uab.edu/uploads/mdocs/UAB-MOPA.pdf
   Google Scholar
• Kawaguchiya M, Urushibara N, Aung MS, Shinagawa M, Takahashi S, Kobayashi N. Serotype distribution, antimicrobial resistance and prevalence of pilus islets in pneumococci following the use of conjugate vaccines. J Med Microbiol. 2017;66:643–50. doi:10.1099/jmm.0.000479.
   PubMed Web of Science ®Google Scholar
• Wantuch PL, Avci FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccines Immunother. 2018;14:2303–09. doi:10.1080/21645515.2018.1470726.
   PubMed Web of Science ®Google Scholar
• Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25:2518–27. doi:10.1016/j.vaccine.2006.09.029.
   PubMed Web of Science ®Google Scholar
• Schutze GE, Mason EO, Barson WJ, Kim KS, Wald ER, Givner LB, Tan TQ, Bradley JS, Yogev R, Kaplan SL. Invasive pneumococcal infections in children with asplenia. Pediatr Infect Dis J. 2002;21:278–82. doi:10.1097/00006454-200204000-00004.
   PubMed Web of Science ®Google Scholar
• Marrie TJ, Tyrrell GJ, Majumdar SR, Eurich DT. Asplenic patients and invasive pneumococcal disease—how bad is it these days? Int J Infect Dis. 2016;51:27–30. doi:10.1016/j.ijid.2016.08.022.
   PubMed Web of Science ®Google Scholar
• Kang JM, Kim EH, Ihn K, Jung I, Han M, Ahn JG. Risk of invasive pneumococcal disease in patients with asplenia/hyposplenism: a nationwide population-based study in Korea, 2009–2018. Int J Infect Dis. 2020;98:486–93. doi:10.1016/j.ijid.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Wang JK, Hsieh KH. Immunologic study of the asplenia syndrome. Pediatr Infect Dis J. 1991;10:819–22. doi:10.1097/00006454-199111000-00005.
   PubMed Web of Science ®Google Scholar
• Rosado MM, Gesualdo F, Marcellini V, Di Sabatino A, Corazza GR, Smacchia MP, Nobili B, Baronci C, Russo L, Rossi F, et al. Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: tailoring better vaccination strategies. Eur J Immunol. 2013;43:2659–70. doi:10.1002/eji.201343577.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011;378:86–97. doi:10.1016/S0140-6736(10)61493-6.
   PubMed Web of Science ®Google Scholar
• Takeshita K, Ishiwada N, Takeuchi N, Takahashi Y, Naito S, Nagasawa K, Hishiki H, Hoshino T, Shimojo N. Pneumococcal IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in Japanese children with a medical history of hematopoietic neoplasms and solid tumors. Jpn J Antibiot. 2018;71:13–21.
   Google Scholar
• Oishi T, Ishiwada N, Matsubara K, Nishi J, Chang B, Tamura K, Akeda Y, Ihara T, Nahm MH, Oishi K. Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease. Vaccine. 2013;31:845–49. doi:10.1016/j.vaccine.2012.11.010.
   PubMed Web of Science ®Google Scholar
• Mikoluc B, Kayhty H, Bernatowska E, Motkowski R. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis. 2008;27:923–28. doi:10.1007/s10096-008-0523-5.
   PubMed Web of Science ®Google Scholar
• Smets F, Bourgois A, Vermylen C, Brichard B, Slacmuylders P, Leyman S, Sokal E. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine. 2007;25:5278–82. doi:10.1016/j.vaccine.2007.05.014.
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, de Weerdt O, van Velzen-Blad H, Biesma DH, Rijkers GT. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients. Vaccine. 2011;29:675–80. doi:10.1016/j.vaccine.2010.11.034.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Osipova IV, Czajka H, Kharit SM, Jackowska T, François N, Habib MA, Borys D. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2–17-year-old children with asplenia or splenic dysfunction: a phase 3 study. Vaccine. 2017;35:5331–38. doi:10.1016/j.vaccine.2017.08.039.
   PubMed Web of Science ®Google Scholar
• Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM. Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma. 2002;53:1037–42. doi:10.1097/00005373-200212000-00001.
   PubMedGoogle Scholar